Results 171 to 180 of about 15,146 (241)

Current Perspectives and Future Directions in the Immunogenicity Landscape of Norovirus Vaccines. [PDF]

J Microbiol Biotechnol
Lee HJ, Yoon D, Jung H, Hong SY, Kim YB, Oh JW.   +5 more
europepmc   +1 more source

Comparative Cytokine and Histology Studies on HPV and Other Viral Vaccinations: No Pathogenicity of HPV Vaccine Adjuvants. [PDF]

Cancer Sci
Shiro R, Sato F, Omura S, Park AM, Nguyen CT, Ahmad I, Rimal S, Kinoshita K, Matsumura N, Tsunoda I.   +9 more
europepmc   +1 more source

Identification Epitope on VP4 Protein of Senecavirus A Recognized by a Monoclonal Antibody

Animal Research and One Health, EarlyView.
This study aims to identify conserved antigenic epitopes on the SVA VP4 protein using monoclonal antibodies, providing valuable tools for further exploring its functions and developing detection methods. SVA VP4 protein was expressed in Escherichia coli and purified with High‐Affinity Ni‐Charged Resin FF.
Liang Meng, Xuyan Xiang, Xinyu Qi, Hanrong Zhou, Peiyu Xiao, Fandan Meng, Tongqing An, Haiwei Wang   +7 more
wiley   +1 more source

Distinct effects of adjuvants on B cell responses to protein or polysaccharide antigens contained in glycoconjugate vaccines. [PDF]

Front Immunol
Budroni S, Faenzi E, Tavarini S, Sammicheli C, Buricchi F, Volpini G, Borgogni E, Spensieri F, Balducci E, Galletti B, Romano MR, D'Oro U, Finco O, Bardelli M.   +13 more
europepmc   +1 more source

Mucosal‐Associated Invariant T Cells in Rheumatic Diseases

Arthritis &Rheumatology, EarlyView.
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek, Virginie Gonzalez, Lucie Beaudoin, Noémie Sénot, Corinne Miceli‐Richard, Yannick Allanore, Agnès Lehuen, Jerôme Avouac   +7 more
wiley   +1 more source

Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity. [PDF]

ACS Appl Mater Interfaces
Kwiatkowski AJ, Schulman JA, Pagendarm HM, Pastora LE, Tossberg JT, Zhang R, Chada NC, Woodruff ME, Sheehy TL, Arora K, Karijolich J, Aune TM, Wilson JT.   +12 more
europepmc   +1 more source

Case‐Based Immunology: B Cells and Systemic Sclerosis Interstitial Lung Disease

Arthritis &Rheumatology, EarlyView.
Interstitial lung disease (ILD) is an important complication of systemic sclerosis (SSc), with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to US Food and Drug Administration–approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of ILDs of other systemic autoimmune
Nina Goldman, Voon Ong, Christopher P. Denton   +2 more
wiley   +1 more source

<i>Rickettsia rickettsii</i> inactivated whole cell antigen vaccine protects against Rocky Mountain spotted fever independent of the adjuvant used. [PDF]

Infect Immun
Latré de Laté P, Stoll IM, Ferm J, Madesh S, Ferm D, Chauhan D, Choudhury D, Liu H, Yadav A, Ganta S, Kim DY, McGill JL, Ganta RR.   +12 more
europepmc   +1 more source

Serum Cytokine Profiling Differentiates Underlying Diseases in Cytokine Storm Syndrome

Arthritis &Rheumatology, EarlyView.
Serum cytokine profiling was performed using Luminex (48 cytokines) and ELISA (5 cytokines). Assessment of key cytokines (IFN‐α, IL‐18, IL‐6, CXCL9) delineated five dominant inflammatory patterns: I, IFN‐α–dominant CSS; II, IL‐18–dominant CSS; III, IL‐6–dominant CSS; IV, IFN‐γ–dominant CSS; and V, IL‐6 & IFN‐γ intermediate CSS.
Shuya Kaneko, Maho Hatano, Asami Shimbo, Futaba Miyaoka, Hitoshi Irabu, Yuko Akutsu, Yuko Hayashi, Mao Mizuta, Yasuo Nakagishi, Keiji Akamine, Naomi Iwata, Kenji Furuno, Takayuki Tanaka, Kazuyuki Ueno, Shuhei Fujita, Koji Yokoyama, Toshinori Minato, Kazushi Izawa, Takahiro Yasumi, Tadashi Matsubayashi, Tadashi Hosoya, Hiroki Nishikawa, Junya Fujimura, Ryoko Asano, Yuko Sugita, Kenichi Watanabe, Anna Kobayashi, Takuya Endo, Katsuhide Eguchi, Ryuta Nishikomori, Ryuhei Yasuoka, Takaki Asano, Miyako Kanno, Kazuya Hamada, Yuji Fujita, Daisuke Hayashi, Shojiro Watanabe, Takeshi Shiba, Shinsuke Yasuda, Masaaki Mori, Hirokazu Kanegane, Masatoshi Takagi, Masaki Shimizu   +42 more
wiley   +1 more source

Efficacy of Telitacicept in Childhood‐Onset Systemic Lupus Erythematosus: A Prospective Multicenter Cohort Study With Inverse Probability of Treatment Weighting –Adjusted Comparison to a Historical Control Group Treated With Belimumab

Arthritis &Rheumatology, EarlyView.
Objective The therapeutic effects of telitacicept combined with standard of care (SoC) in childhood‐onset systemic lupus erythematosus (cSLE) remain unclear. This study aims to evaluate its efficacy in comparison with belimumab combined with SoC.
Chong Luo, Shu Su, Jingyue Liu, Junyu Lin, Jin Song, Zongwen Chen, Yuanyuan Peng, Lijun Jiang, Meng Jia, Li Wang, Xinhui Jiang, Wei Zhang, Zanhua Rong, Bo Zhao, Yajun Wang, Xuemei Tang   +15 more
wiley   +1 more source